Evaluation of Drug-Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors.
Drug-PIN®
EGFR
drug–drug interactions (DDI)
non-small-cell lung cancer (NSCLC)
tyrosine-kinase inhibitors (EGFR-TKIs)
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
05
03
2021
revised:
02
05
2021
accepted:
11
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
(1) Background. The onset of a drug-drug interaction (DDI) may affect treatment efficacy and toxicity of advanced non-small-cell lung cancer (aNSCLC) patients during epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) use. Here we present the use of Drug-PIN
Identifiants
pubmed: 34069851
pii: jpm11050424
doi: 10.3390/jpm11050424
pmc: PMC8157378
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Exp Cell Res. 2014 May 1;323(2):288-96
pubmed: 24631288
Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):833-41
pubmed: 25934831
Oncotarget. 2016 Jul 5;7(27):42208-42215
pubmed: 27283991
J Cell Physiol. 2012 Apr;227(4):1709-20
pubmed: 21688263
FEBS J. 2010 Jan;277(2):316-26
pubmed: 19922467
Theranostics. 2019 Aug 14;9(21):6157-6174
pubmed: 31534543
Cancer Res. 2007 Dec 15;67(24):11867-75
pubmed: 18089817
Ann Oncol. 2015 May;26(5):992-997
pubmed: 25628444
J Oncol Pharm Pract. 2017 Oct;23(7):483-490
pubmed: 27530243
J Res Med Sci. 2013 Jul;18(7):601-10
pubmed: 24516494
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
Int J Clin Pharm. 2013 Jun;35(3):401-7
pubmed: 23283597
Curr Opin Pharmacol. 2012 Dec;12(6):710-6
pubmed: 22824431
J Am Coll Cardiol. 2008 Nov 25;52(22):1769-81
pubmed: 19022156
J Natl Cancer Inst. 2007 Apr 18;99(8):592-600
pubmed: 17440160
Int J Cancer. 2017 Apr 1;140(7):1645-1652
pubmed: 28006834
Cancer Res. 2016 Apr 15;76(8):2063-70
pubmed: 27197250
Tumour Biol. 2015 Aug;36(8):5801-5
pubmed: 25702091
Int J Clin Pharm. 2014 Dec;36(6):1251-9
pubmed: 25326824
Oncologist. 2006 Jul-Aug;11(7):732-41
pubmed: 16880232
Pharm World Sci. 2010 Oct;32(5):575-80
pubmed: 20645002
Lancet. 2012 Aug 11;380(9841):581-90
pubmed: 22607822
Clin Cancer Res. 2006 Jan 15;12(2):536-42
pubmed: 16428497
J Am Geriatr Soc. 1996 Aug;44(8):944-8
pubmed: 8708305
Onco Targets Ther. 2019 Jul 09;12:5467-5484
pubmed: 31371986
PLoS One. 2017 Feb 3;12(2):e0171137
pubmed: 28158206
Lancet Oncol. 2014 Jul;15(8):e315-26
pubmed: 24988935
Cancer Treat Rev. 2014 Sep;40(8):917-26
pubmed: 25027951
Ann Oncol. 2011 Oct;22(10):2334-41
pubmed: 21343376
Br J Cancer. 2013 Mar 19;108(5):1071-8
pubmed: 23412102
J Cell Physiol. 2018 Sep;233(9):6722-6732
pubmed: 29215723
Oncotarget. 2016 Dec 20;7(51):85542-85550
pubmed: 27907909
Ann Pharmacother. 1992 Feb;26(2):234-7
pubmed: 1554938
Int J Clin Pharm. 2013 Aug;35(4):554-9
pubmed: 23585184
PLoS One. 2016 Feb 19;11(2):e0149722
pubmed: 26894507
Mol Oncol. 2012 Feb;6(1):62-72
pubmed: 22153388
J Cell Physiol. 2011 Sep;226(9):2316-28
pubmed: 21660955
Invest New Drugs. 2011 Oct;29(5):945-52
pubmed: 20464445